Denmark reports first case of resistance to swine flu treatment

June 29, 2009

Danish health officials on Monday reported the first case of resistance to Tamiflu, considered to be the most effective treatment for swine flu by the World Health Organization.

The Danish national is no longer suffering from the illness and is not displaying symptoms, the Danish Institute of Serology said in a statement.

The patient had been in direct contact with a swine flu victim and so was given a dosage of Tamiflu as a preventative measure.

But she still contracted the virus after her body resisted the treatment, leading doctors to give her another type of medication, , made by British pharmaceutical giant GlaxoSmithKline.

Nils Strandberg, the institute's director, said he was satisfied with the methods used to monitor swine flu, adding that "the spontaneous mutation of a flu virus is not unusual".

He refused to rule out new mutations of the virus appearing in the future and stressed this case posed no risk to public health or the recommendations on the use of Tamiflu.

Case of swine flu treatment resistance 'expected': Roche

Swiss drugs company Roche said Monday that a swine flu patient's resistance to treatment with its Tamiflu drug in Denmark was expected and likely to be an individual case.

"This was very much expected," said David Reddy, Roche's pandemic task force leader.

"It doesn't mean the circulating virus is resistant to Tamiflu," he told AFP.

Danish health officials on Monday reported the first case of resistance in a patient treated with Tamiflu, an antiviral drug that is one of the key influenza treatments recommended by the World Health Organization.

The Dane is no longer suffering from the illness and is not displaying symptoms, the Danish Institute of Serology said in a statement.

Reddy said the case was within the 0.5 percent rate of case resistance to Tamiflu established in clinical trials.

Other people also infected with the Dane were treated with Tamiflu, and Reddy suggested it showed that the individual patient had some form of resistance rather than the A(H1N1) influenza virus.

The patient was given another type of medication, Relenza, made by British pharmaceutical giant GlaxoSmithKline.

(c) 2009 AFP

Related Stories

Recommended for you

Study opens new avenue in quest to develop tuberculosis vaccine

November 24, 2017
A team of scientists led by the University of Southampton has taken an important step forward in research efforts that could one day lead to an effective vaccine against the world's deadliest infectious disease.

Four simple tests could help GPs spot pneumonia and reduce unnecessary antibiotics

November 23, 2017
Testing for fever, high pulse rate, crackly breath sounds, and low oxygen levels could be key to helping GPs distinguish pneumonia from less serious infections, according to a large study published in the European Respiratory ...

New approach to tracking how deadly 'superbugs' travel could slow their spread

November 22, 2017
Killer bacteria - ones that have out-evolved our best antibiotics—may not go away anytime soon. But a new approach to tracking their spread could eventually give us a fighting chance to keep their death toll down.

Research points to diagnostic test for top cause of liver transplant in kids

November 22, 2017
Biliary atresia is the most common cause of liver transplants for children in the United States. Now researchers report in Science Translational Medicine finding a strong biomarker candidate that could be used for earlier ...

Alcohol consumption and metabolic factors act together to increase the risk of severe liver disease

November 22, 2017
A new study provides insights into the interaction between alcohol consumption and metabolic factors in predicting severe liver disease in the general population. The findings, which are published in Hepatology, indicate ...

Metabolites altered in chronic kidney disease

November 22, 2017
Chronic kidney disease (CKD) affects 1 in 7 people in the United States, according to the U.S. National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK). These individuals have a very high risk of cardiovascular ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.